Sanofi moves further into next-gen oncology
Sanofi’s latest acquisition sees the group pay $1bn for the private immuno-oncology company Amunix.
Bavarian Nordic goes it alone, for now
Phase 3 in RSV will begin without a partner, while decent Covid-19 booster data pave the way for pivotal development.
RSVVW 2021 – Pfizer gets maternal
Positive phase 2 data with the group’s maternal RSV vaccine set up a busy 2022 for work on the infectious disease.
Bavarian Nordic gets a vaccine booster
The Danish group reports promising mid-stage data with its respiratory syncytial virus vaccine, but competition is fierce.
Sigilon hold hurts ahead of key haemophilia meeting
After a patient develops inhibitors questions emerge about a new approach to treating haemophilia A.
Novartis’s canakinumab cancer test approaches
Will it be a new class of cancer drug or another failure for Novartis’s IL-1 inhibitor?
Glaxo moves up a place in the RSV treatment race
The start of a pivotal trial of Glaxosmithkline’s RSV vaccine adds another late-stage project to the pipeline for this underserved disease category.
Some of biopharma’s biggest assets face a solo existence
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Another complement factor enters the deal-making frame
Sobi picking up rights to Apellis’s complement factor C3 inhibitor adds to earlier deals focused on C5, D and anti-FcRn antibodies.
